



(11) **EP 1 636 268 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07K 16/18 (2006.01)

(86) International application number:
PCT/US2004/017514

(48) Corrigendum issued on:
21.03.2012 Bulletin 2012/12

(87) International publication number:
WO 2004/108895 (16.12.2004 Gazette 2004/51)

(45) Date of publication and mention
of the grant of the patent:
15.02.2012 Bulletin 2012/07

(21) Application number: **04776252.1**

(22) Date of filing: **01.06.2004**

(54) **HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE**
HUMANISIERTE ANTIKÖRPER, DIE BETA AMYLOID-PEPTID ERKENNEN
ANTICORPS HUMANISES QUI RECONNAISSENT LE PEPTIDE BETA-AMYOIDE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL HR LT LV MK

(74) Representative: **Mercer, Christopher Paul**
Carpmaels & Ransford
One Southampton Row
London
WC1B 5HA (GB)

(30) Priority: **30.05.2003 US 474654 P**

(56) References cited:
EP-A1- 0 921 189 WO-A-95/07301
WO-A2-02/088306 US-A1- 2004 082 762
US-B1- 6 743 427 US-B1- 6 750 324

(43) Date of publication of application:
22.03.2006 Bulletin 2006/12

(73) Proprietors:
• **Janssen Alzheimer Immunotherapy**
Dublin 2 (IE)
• **Wyeth LLC**
Madison, NJ 07940 (US)

• **BARD F ET AL: "Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 4, 18 February 2003 (2003-02-18), pages 2023-2028, XP002982464 ISSN: 0027-8424**
• **QUEEN C ET AL: "A HUMANIZED ANTIBODY THAT BINDS TO THE INTERLEUKIN 2 RECEPTOR" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 86, no. 24, 1 December 1989 (1989-12-01), pages 10029-10033, XP000310534 ISSN: 0027-8424**

(72) Inventors:
• **BASI, Guriq**
Palo Alto, CA 94303 (US)
• **SALDANHA, Jose, W.**
Enfield,
EN1 3BD (GB)
• **BARD, Frédérique**
Pacifica, CA 94044 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 636 268 B8

- SALDANHA J W ET AL: "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells" MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 36, 1999, pages 709-719, XP007901434 ISSN: 0161-5890
- SOLOMON B.: 'Immunological approaches as therapy for Alzheimer's disease' EXPERT OPIN BIOL THER. vol. 2, no. 8, December 2002, pages 907 - 917, XP002971402
- HOLTZMAND.M. ET AL: 'Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease' ADVANCED DRUG DELIVERY REVIEWS vol. 54, no. 12, pages 1603 - 1613, XP002982465
- DODEL R.C. ET AL: 'Immunotherapy for Alzheimer's disease' LANCET NEUROLOGY vol. 2, no. 4, April 2003, pages 215 - 220, XP004810319